NKGen Biotech, Inc. NKGN

NKGN Company Overview

NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development of natural killer (NK) cell–based immunotherapies. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on leveraging a patient’s own immune system to target cancer and neurodegenerative diseases. Its core development program centers on autologous NK cell therapy intended to enhance immune response without genetic modification.

The company’s principal product candidate is SNK01, an autologous, non-genetically modified NK cell therapy being evaluated in multiple clinical indications, including Alzheimer’s disease, Parkinson’s disease, and certain oncology settings. NKGen positions itself as differentiated from CAR-NK and CAR-T developers by focusing on scalable, non-engineered NK cell expansion, which may reduce manufacturing complexity and safety risks. NKGen Biotech was founded in 2017 and became a publicly traded company in 2023 through a merger transaction, after which its common stock began trading on Nasdaq under the ticker NKGN.